UCB, a leader in epilepsy and the maker of VIMPAT®, an add-on medication used to treat partial-onset seizures in adults with epilepsy, is committed to transforming the lives of people living with severe diseases through conducting scientific research, developing treatments and creating programming for health care professionals and patients. The company's latest initiative is a simple but important step in helping the epilepsy community obtain additional or improved seizure control and encourages the public to shift their mindset, take action and support a nationwide movement of people ready to do more. Pledges can range from improving communication, educating friends and family about epilepsy or encouraging others not to settle for their current level of seizure control. More information and tips for living the Pledge can be found online.
VIMPAT® (lacosamide) is a prescription medicine that is used with other medicines to treat partial onset seizures in people 17 years of age and older with epilepsy.
IMPORTANT SAFETY INFORMATION
VIMPAT® may not be for everyone. Ask your healthcare provider if VIMPAT® is right for you.
WARNINGS AND PRECAUTIONS
Antiepileptic drugs, including VIMPAT®, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your healthcare provider right away if you have new or worsening symptoms of depression, any unusual changes in mood or behavior, or suicidal thoughts, behavior, or thoughts about self-harm that you have never had before or may be worse than before.
Do not stop taking VIMPAT® withou
|SOURCE UCB, Inc.|
Copyright©2012 PR Newswire.
All rights reserved